Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno N, Prat A, Chae Y, Lee K, Niikura N, Park Y, Xu B, Wang X, Gil-Gil M, Li W, Pierga J-Y, Im S-A, Moore H, Rugo H, Yerushalmi R, Zagouri F, Gombos A, Kim S-B, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron D Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9-20. doi:10.1056/NEJMoa2203690
du Manoir S, Delpech H, Orsetti B, Jacot W, Pirot N, Noel J, Colombo P-E, Sardet C, Theillet C In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6, and SOX2. J Pathol. 2022;257(3):367-378. doi:10.1002/path.5896
Jacot W, Heudel P-E, Fraisse J, Gourgou S, Guiu S, Dalenc F, Pistilli B, Campone M, Levy C, Debled M, Leheurteur M, Chaix M, Lefeuvre C, Goncalves A, Uwer L, Ferrero J-M, Eymard J-C, Petit T, Mouret-Reynier M-A, Courtinard C, Cottu P, Robain M, Mailliez A Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. Int. J. Cancer. May 14, 2019. doi:10.1002/ijc.32402
Fonti C, Saumet A, Abi-Khalil A, Orsetti B, Cleroux E, Bender A, Dumas M, Schmitt E, Colinge J, Jacot W, Weber M, Sardet C, du Manoir S, Theillet C Distinct oncogenes drive different genome and epigenome alterations in human mammary epithelial cells. Int. J. Cancer. 2019;145(5):1299-1311. doi:10.1002/ijc.32413
Idoux-Gillet Y, Nassour M, Lakis E, Bonini F, Theillet C, Savagner P Slug/Pcad pathway controls epithelial cell dynamics in mammary gland and breast carcinoma. Oncogene. 2018;37(5):578-588. doi:10.1038/onc.2017.355
Arnould S, Rodier G, Matar G, Vincent C, Pirot N, Delorme Y, Buscail Y, Noël J, Lachambre S, Jarlier M, Bernex F, Delpech H, Vidalain P, Janin Y, Theillet C, Sardet C Checkpoint kinase 1 inhibition sensitises transformed cells to dihydroorotate dehydrogenase inhibition. Oncotarget. 2017;8(56):95206-95222. doi:10.18632/oncotarget.19199
Lacroix M, Rodier G, Kirsh O, Delpech H, Seyran B, Gayte L, Casas F, Pessemesse L, Heuillet M, Bellvert F, Portais J-C, Berthet C, Bernex F, Brivet M, Boutron A, Le Cam L, Sardet C E4F1 controls a transcriptional program essential for pyruvate dehydrogenase activity. Proc. Natl. Acad. Sci. U.S.A.. 2016;113(39):10998-11003. doi:10.1073/pnas.1602754113
Rodier G, Kirsh O, Baraibar M, Houles T, Lacroix M, Delpech H, Hatchi E, Arnould S, Severac D, Dubois E, Caramel J, Julien E, Friguet B, Le Cam L, Sardet C The transcription factor E4F1 coordinates CHK1-dependent checkpoint and mitochondrial functions. Cell reports. 2015;11. doi:10.1016/j.celrep.2015.03.024
Colombo P, du Manoir S, Orsett B, Bras-Goncalves R, Lambros M, MacKay A, Nguyen T, Boissiere F, Pourquier D, Bibeau F, Reis-Filho J, Theillet C Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure. Oncotarget. 2015;6. doi:10.18632/oncotarget.5069
du Manoir S, Orsetti B, Bras-Gonçalves R, Nguyen T-T, Lasorsa L, Boissière F, Massemin B, Colombo P-E, Bibeau F, Jacot W, Theillet C Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse. Mol Oncol. 2014;8(2):431-443. doi:10.1016/j.molonc.2013.11.010
Institut de Recherche en Cancérologie de
